Evolution of diagnostic criteria and new insights into clinical testing in mixed connective tissue disease; anti-survival motor neuron complex antibody as a novel marker of severity of the disease
| Autor: | Satoshi Kubo, Yoshiya Tanaka |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Immunological Medicine, Vol 47, Iss 2, Pp 52-57 (2024) |
| Druh dokumentu: | article |
| ISSN: | 25785826 2578-5826 |
| DOI: | 10.1080/25785826.2024.2338593 |
| Popis: | AbstractMixed connective tissue disease (MCTD) is an autoimmune disorder characterized by a combination of clinical features from systemic lupus erythematosus, systemic sclerosis, and inflammatory muscle disease, along with the presence of positive anti-U1-ribonucleoprotein (U1-RNP) antibodies. The exact etiology of the disease remains unclear, but it is believed to involve vascular damage within the context of heightened autoimmune responses. Consequently, Raynaud’s phenomenon and pulmonary arterial hypertension are observed in patients with MCTD. While specific biomarkers for MCTD have not yet been identified, the recent study of the utility of anti-survival motor neuron complex (SMN) antibodies in MCTD suggests a promising avenue for further research and the accumulation of additional evidence. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|